中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2009年
3期
447-448
,共2页
糖尿病,2型%内膜中层厚度%基质金属蛋白酶-9%C反应蛋白质%罗格列酮
糖尿病,2型%內膜中層厚度%基質金屬蛋白酶-9%C反應蛋白質%囉格列酮
당뇨병,2형%내막중층후도%기질금속단백매-9%C반응단백질%라격렬동
Diabetes mellitus,type 2%Intimamedia thickness%Matrix metalloproteinase-9%C-Reactive Protein%Rosiglitazone
目的 评价2型糖尿病患者经罗格列酮长期治疗后颈动脉内膜中层厚度(IMT)的变化及机制.方法 选择59例2型糖尿病伴肥胖患者,随机分成对照组(29例)与治疗组(30例),治疗组加用罗格列酮治疗24个月,治疗前后应用高频超声检测IMT及基质金属蛋白酶-9(MMP-9)、C-反应蛋白(CRP)的变化.结果 与对照组比较,治疗组IMT降低(P＜0.05),治疗组治疗后血清MMP-9与CRP分别为(253.4±97.5)ng/L和(1.15±0.96)mg/L,对照组分别为(361.8±101.7)ng/L和(2.18±2.01)mg/L.两组比较差异有统计学意义(P＜0.01).结论 罗格列酮能延缓2型糖尿病患者颈动脉粥样硬化的进展,其作用机制可能通过改善MMP-9和CRP而实现.
目的 評價2型糖尿病患者經囉格列酮長期治療後頸動脈內膜中層厚度(IMT)的變化及機製.方法 選擇59例2型糖尿病伴肥胖患者,隨機分成對照組(29例)與治療組(30例),治療組加用囉格列酮治療24箇月,治療前後應用高頻超聲檢測IMT及基質金屬蛋白酶-9(MMP-9)、C-反應蛋白(CRP)的變化.結果 與對照組比較,治療組IMT降低(P＜0.05),治療組治療後血清MMP-9與CRP分彆為(253.4±97.5)ng/L和(1.15±0.96)mg/L,對照組分彆為(361.8±101.7)ng/L和(2.18±2.01)mg/L.兩組比較差異有統計學意義(P＜0.01).結論 囉格列酮能延緩2型糖尿病患者頸動脈粥樣硬化的進展,其作用機製可能通過改善MMP-9和CRP而實現.
목적 평개2형당뇨병환자경라격렬동장기치료후경동맥내막중층후도(IMT)적변화급궤제.방법 선택59례2형당뇨병반비반환자,수궤분성대조조(29례)여치료조(30례),치료조가용라격렬동치료24개월,치료전후응용고빈초성검측IMT급기질금속단백매-9(MMP-9)、C-반응단백(CRP)적변화.결과 여대조조비교,치료조IMT강저(P＜0.05),치료조치료후혈청MMP-9여CRP분별위(253.4±97.5)ng/L화(1.15±0.96)mg/L,대조조분별위(361.8±101.7)ng/L화(2.18±2.01)mg/L.량조비교차이유통계학의의(P＜0.01).결론 라격렬동능연완2형당뇨병환자경동맥죽양경화적진전,기작용궤제가능통과개선MMP-9화CRP이실현.
Objective To investigate the effects and mechanism of rosiglitazone on carotid intima-media thickness(IMT)in patients with type 2 diabetes mellitus(DM)by carotid ultrssonography.Methods Fifty-nine patienta with obese DM were divided into two groups randomly:patients in control group(n=29)received routine therapy.and patients in treatment group(n=30)received rosiglitzone with routine therapy for 24 months.Carotid IMT was measured by carotid ultrasonography pre-and post-therapy.The level of ma-trix metalloproteinase-9(MMPO)and C-reactive protein(CRP)were assayed.Results Compared with control group,the IMT was decreased following irosiglitazone therapy(P＜0.05).The concentrations of MMP-9 and CRP in patients in the treatment group were (253.4±97.5)ng/L and(1.15±0.96)mg/L,and those in the control group were(361.8±101.7)ng/L and (2.18±2.01)mg/L,which were significantly impmved.Conclusion Rosiglitazone could retard atherosclerosis progression in obese patients with type 2 DM which was achieved through improving MMP-9 and CRP.
